Effect of oral sebacic Acid on postprandial glycemia, insulinemia, and glucose rate of appearance in type 2 diabetes.
OBJECTIVE
Dicarboxylic acids are natural products with the potential of being an alternate dietary source of energy. We aimed to evaluate the effect of sebacic acid (a 10-carbon dicarboxylic acid; C10) ingestion on postprandial glycemia and glucose rate of appearance (Ra) in healthy and type 2 diabetic subjects. Furthermore, the effect of C10 on insulin-mediated glucose uptake and on GLUT4 expression was assessed in L6 muscle cells in vitro.


METHODS
Subjects ingested a mixed meal (50% carbohydrates, 15% proteins, and 35% lipids) containing 0 g (control) or 10 g C10 in addition to the meal or 23 g C10 as a substitute of fats.


RESULTS
In type 2 diabetic subjects, the incremental glucose area under the curve (AUC) decreased by 42% (P<0.05) and 70% (P<0.05) in the 10 g C10 and 23 g C10 groups, respectively. At the largest amounts used, C10 reduced the glucose AUC in healthy volunteers also. When fats were substituted with 23 g C10, AUC of Ra was significantly reduced on the order of 18% (P<0.05) in both healthy and diabetic subjects. The insulin-dependent glucose uptake by L6 cells was increased in the presence of C10 (38.7±10.3 vs. 11.4±5.4%; P=0.026). This increase was associated with a 1.7-fold raise of GLUT4.


CONCLUSIONS
Sebacic acid significantly reduced hyperglycemia after a meal in type 2 diabetic subjects. This beneficial effect was associated with a reduction in glucose Ra, probably due to lowered hepatic glucose output and increased peripheral glucose disposal.
Iaconelli
Amerigo
A
Department of Internal Medicine, Catholic University of Rome, Rome, Italy.
Gastaldelli
Amalia
A
Chiellini
Chiara
C
Gniuli
Donatella
D
Favuzzi
Angela
A
Binnert
Christophe
C
Macé
Katherine
K
Mingrone
Geltrude
G
D015502:Absorptiometry, Photon; D000818:Animals; D001692:Biological Transport / Q000187:drug effects*; D001786:Blood Glucose / Q000378:metabolism*; D015153:Blotting, Western; D001823:Body Composition / Q000187:drug effects; D002096:C-Peptide / Q000097:blood; D002460:Cell Line; D003652:Decanoic Acids / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000178:diet therapy* / Q000378:metabolism*; D003998:Dicarboxylic Acids / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D047468:Immunoprecipitation; D007328:Insulin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D019518:Postprandial Period / Q000187:drug effects*; D051381:Rats
D001786:Blood Glucose; D002096:C-Peptide; D003652:Decanoic Acids; D003998:Dicarboxylic Acids; D007328:Insulin; C011107:sebacic acid